16S rRNA Bacterial Identification in Evaluation of Orthopedic Infections and its Limited Role in Antimicrobial Stewardship Authors: Joseph A McBride, Memee Moua, Alana Sterkel, Eduard Matkovic, William Rehrauer, Jens Eickhoff, Marin L Schweizer, David Andes Published: 2026 ABSTRACT AbstractBackground16S bacterial identification is a molecular diagnostic test that can aid in the diagnosis and management of orthopedic infections. The study aims to describe the diagnostic value of 16S for orthopedic infections and whether results of 16S impact antibiotic de-escalation.MethodsThis retrospective cohort study included all patient encounters with 16S performed for evaluation of orthopedic infections at 1 Midwest academic center over a 5-year prepandemic period. Qualitative descriptions of the clinical cases, antibiotics, and 16S results were evaluated.ResultsFour hundred fifty-two episodes were included for analysis. Overall, 9.5% of 16S tests detected bacteria. The most common indication for testing was for evaluation of septic arthritis. For diagnosing infectious episodes, 16S had a sensitivity of 15.5%, a specificity of 98%, a positive predictive value of 90.7%, and a negative predictive value of 47.9%. Analysis of all episodes demonstrated antibiotic de-escalation from pre-16S to post-16S time points. However, antibiotics were continued for a large number of episodes with negative 16S when judged as infectious by the treating clinician.Conclusions16S bacterial identification aided in the diagnosis and treatment of only a minority of orthopedic infections and results did not serve as a useful tool for antimicrobial de-escalation.Keywords: 16S bacterial identification, antimicrobial stewardship, diagnostic stewardship, musculoskeletal infections, orthopedic infections Orthopedic and musculoskeletal infections can be challenging to diagnose, demanding to treat, expensive to manage, and crippling to patients. Patient histories and presentation often vary, and culture-negative infections are common. When possible, microbiologic identification of pathogens eliminates diagnostic uncertainty and promotes targeted antimicrobial therapy. 16S bacterial identification is a molecular diagnostic test that amplifies prokaryotic bacterial ribosomal ribonucleic acid (rRNA) and aids in the identification and diagnosis of bacterial infections. 16S rRNA strands serve as scaffolding for ribosomal proteins of the 30S subunit in prokaryotic ribosomes. Each 16S rRNA strand consists of ∼1500 base pairs of rRNA with both variable and conserved regions across bacterial species. Variable regions can be sequenced for phylogenetic classification of bacteria and mycobacteria. The identification of bacteria via 16S diagnostics can assist in the diagnosis of bacterial infections including infections caused by fastidious pathogens as well as infections where standard cultures are confounded by antibiotic pretreatment [1]. We aim to describe the diagnostic value of 16S bacterial identification for evaluation of orthopedic infections and whether results of 16S impact antibiotic de-escalation. METHODS This retrospective cohort study included all patients with a 16S test performed for the evaluation of orthopedic and musculoskeletal infections at the University of Wisconsin between November 9, 2012, and January 4, 2017. There were no exclusion criteria. The study met criteria for UW Institutional Review Board exemption. Our primary aim was to perform a qualitative description of the clinical cases with 16S results. The analysis included the indication for 16S testing, the sensitivity and specificity at various tissue sites, the impact of antibiotic pre-exposure on 16S positivity, and its contribution to the ultimate diagnosis. Our secondary aim was to determine the impact of 16S results on antimicrobial prescribing. The results were analyzed through retrospective review of patient care episodes. Episodes were defined as antibiotic decision points. If an episode had more than one 16S result (eg, surgery with multiple samples sent), we evaluated the sample that most likely led to a final diagnosis (eg, bone over body fluid) or deferred to the positive result. These linked 16S results were combined to form 1 episode. 16S samples sent >7 days from one another were counted as distinct episodes. Each episode was classified as infectious or noninfectious through review of the documentation and antibiotic plan by the study authors. Infectious episodes were defined as episodes the treating clinical service judged to be infectious through review of the documentation and antibiotic plan by the study authors. Noninfectious episodes were defined as episodes the treating clinical service judged to be noninfectious by the same means. Infections outside the orthopedic area of concern, such as a patient with bacterial pneumonia undergoing evaluation for prosthetic joint infection, were classified as “noninfectious” if orthopedic infections were ruled out by the treating clinical services. The 16S rRNA sequencing assay performed at the University of Wisconsin molecular diagnostic lab reports genus or genus/species only when sequence homology is at least 98% to reference SmartGene database entries (www.smartgene.com; SmartGene North American operations in Research Triangle Park, NC, USA). It demonstrated high analytical accuracy, precision, and robust performance across instruments and pre-analytical conditions. Analytical sensitivity studies showed that both MagNA Pure extractors and real-time polymerase chain reaction (PCR) platforms (LightCycler 480, Roche Diagnostics) generated reliable sequence data (ABI 3500; ThermoFisher Scientific) with as few as ∼104 bacterial cells as input. Within-run precision was confirmed by 3 operators running 5 organisms through the full workflow on both extractors and amplification platforms with consistent organism identifications across operators and databases, and day-to-day imprecision was assessed using alternating positive controls (Haemophilus influenzae, Pseudomonas aeruginosa, Staphylococcus aureus) and negative buffer controls, all of which repeatedly produced the expected identification or “no bacteria identified” result over multiple testing days. Accuracy/correlation studies using 60 American Type Culture Collection (ATCC) or stock organisms showed 100% agreement for 59 evaluable samples (1 excluded for low cell count), with an additional 100% concordance for 37 clinical isolates and 13 direct clinical specimens when compared with in-house culture and/or reference clinical laboratory 16S results. Sample stability was supported by consistent crossing points, melting temperatures, and sequence identifications for 3 representative organisms over 0, 3, and 7 days at 4°C, leading to an acceptance of up to 7-day refrigerated stability, while interference was managed by aligning with existing molecular assays and explicitly excluding heparinized samples due to known PCR inhibition; carryover was considered negligible given single-use plastics and prior carryover validation studies, and overall performance exceeded the predefined quality requirement of at least 95% correlation with ATCC or reference laboratory identifications. Bacterial organisms are identified (genus) or speciated (genus and species) by 16S rRNA DNA sequencing after assessing and integrating numerous factors, including the analytical quality of real-time PCR and DNA sequencing data, the alignment(s) of DNA sequence(s) to the database, the correlation to phenotypic characteristics, when available, from clinical microbiology, and the overall clinical presentation of the patient. The 16S testing was performed twice weekly. 16S testing could be ordered by any clinician and did not require infectious disease or pathology approval. The lab performed the 16S analysis if (1) the bacterial cultures from the same anatomic site had finalized without growth or (2) pending bacterial cultures had no growth at 48 hours. Positive 16S (16S+) was defined as amplified bacterial rRNA. Negative 16S (16S-) was defined as no amplification of bacterial rRNA. Positive microbiology (Micro+) was defined as bacteria detected on gram stain or bacterial growth from either (1) samples from the same anatomic site as the 16S sample or (2) samples from other body sites that contributed to the diagnosis such as blood cultures. Negative microbiology (Micro-) was defined as no bacteria detected on gram stain and no bacterial growth on all cultures. Each of the 452 episodes was categorized into 15 subgroups based on the final diagnosis, 16S results, and associated diagnostic microbiology (Figure 1): (1) Subgroup A: all episodes; (2) Subgroup B: all infectious episodes; (3) Subgroup C: all noninfectious episodes; (4) Subgroup D: all infectious episodes with 16S+; (5) Subgroup E: all infectious episodes with 16S-; (6) Subgroup F: all noninfectious episodes with 16S+; (7) Subgroup G: all noninfectious episodes with 16S-; (8) Subgroup H or “16S redundant”: infectious episodes with both 16S+ and Micro+; (9) Subgroup I or “16S dependent”: infectious episodes with 16S+ and Micro-; (10) Subgroup J or “culture diagnosed”: infectious episodes with 16S- and Micro+; (11) Subgroup K or “diagnosed via history and physical”: infectious episodes with 16S- and Micro-; (12) Subgroup L or “false positive 16S and cultures”: noninfectious episodes with 16S+ and Micro+; (13) Subgroup M or “false positive 16S”: noninfectious episodes with 16S+ and Micro-; (14) Subgroup N or “false positive cultures”: noninfectious episodes with 16S- and Micro+; (15) Subgroup O or “infection ruled out”: noninfectious episodes with 16S- and Micro-. 16S subgroups. Subgroup A: all episodes; Subgroup B: all infectious episodes; Subgroup C: all noninfectious episodes; Subgroup D: all infectious episodes with positive 16S; Subgroup E: all infectious episodes with negative 16S; Subgroup F: all noninfectious episodes with positive 16S; Subgroup G: all noninfectious episodes with negative 16S; Subgroup H: infectious episodes with positive 16S and positive microbiology; Subgroup I: infectious episodes with positive 16S and negative microbiology; Subgroup J: infectious episodes with negative 16S and positive microbiology; Subgroup K: infectious episodes with negative 16S and negative microbiology; Subgroup L: noninfectious episodes with positive 16S and positive microbiology; Subgroup M: noninfectious episodes with positive 16S and negative microbiology; Subgroup N: noninfectious episodes with negative 16S and positive microbiology; Subgroup O: infectious episodes with negative 16S and negative microbiology. Antibiotic de-escalation was determined by comparing the initial antibiotics at the time of the 16S sample order with the antibiotic plan after 16S result. Pre-16S antibiotics were defined as antibiotics ordered and administered at the time of the 16S order. Post-16S antibiotics were defined as antibiotics ordered and administered after the reported 16S result. The antibiotics were determined via consensus chart review by 2 study authors. The number, the spectrum of activity, and route of antibiotics were assessed. Anti-methicillin-resistant S. aureus (MRSA) agents included vancomycin, daptomycin, linezolid, ceftaroline, dalbavancin, oritavancin, trimethoprim-sulfamethoxazole, clindamycin, and doxycycline. Antipseudomonal agents included piperacillin-tazobactam, ceftazidime, cefepime, meropenem, imipenem-cilastatin, ciprofloxacin, levofloxacin, gentamicin, and tobramycin. In 2023, the Clinical & Laboratory Standards Institute (CLSI) updated P. aeruginosa breakpoints eliminated gentamicin as a suggested antipseudomonal treatment option [2]. Nevertheless, in this series gentamicin is included as an antipseudomonal agent as it was an acceptable treatment option during the study years. We summarized episodes of 16S positivity and infections using mean values with standard deviations for continuous variables and raw counts with percentages for categorical variables. We made comparisons in mean values using the Student t test, and we used Fisher exact tests for all categorical comparisons. Predictors of 16S positivity were identified using logistic regression analysis models. The impact of 16S on antibiotic prescribing was assessed using paired Student t test-to-test differences between pre and post measures. We used a significance level of .05 to indicate all statistically significant associations. All analyses were conducted using STATA, version 17. RESULTS Overall, 452 unique 16S episodes from 380 distinct patients were included for analysis. Patients ranged from 1 to 91 years of age (mean, 54.9 years). Only 9.5% of 16S tests (43/452) detected bacteria (Table 1). Indications for 16S testing included evaluation for septic arthritis, osteomyelitis, surgical site infections, bursitis, skin and soft tissue infections, and tenosynovitis. Episodes included evaluation for native bone and joint infections, prosthetic joint infections, and hardware-associated non–prosthetic joint infections. The source tissue included synovial fluid, bone, tissue, body fluid, and bursa fluid. The knee (32.3%, 146/452) and the hip (29.6%, 134/452) were the most common anatomic sites of sampling, followed by the foot (6.4%, 29/452), shoulder (4.6%, 21/452), tibia (4.4%, 20/452), femur (3.8%, 17/452), spine (3.8%, 17/452), ankle (2.7%, 12/452), hand (2.2%, 10/452), pelvis (2.2%, 10/452), wrist (2.0%, 9/452), elbow (1.8%, 8/452), thigh (1.3%, 6/452), humerus (1.1%, 5/452), radius (0.66%, 3/452), fibula (0.44%, 2/452), forearm (0.44%, 2/452), sternoclavicular joint (0.44%, 2/452), and ulna (0.22%, 1/452). Predictors of 16S positivity included antibiotics at time of order, infectious disease consultation, and positive associated microbiology (Table 2). Table 1.Qualitative Analysis of 16S Results (n = 452)Overall16S Positives (n = 43), No. (%)16S Negatives (n = 409), No. (%) P ValueAge [range, 1–91 y] Mean54.951.455.3.26Gender Male252 (55.7)26 (60.5)226 (55.3).51 Female200 (44.3)17 (39.5)183 (44.7)Indication Septic arthritis320 (70.8)23 (53.5)297 (72.6) .02 Osteomyelitis110 (24.3)15 (34.9)95 (23.2) Surgical site infection7 (1.6)2 (4.7)5 (1.2) Bursitis5 (1.1)1 (2.3)4 (1.0) Skin/soft tissue infection5 (1.1)2 (4.6)3 (0.7) Tenosynovitis5 (1.1)0 (0)5 (1.2)Type of infection Native209 (46.2)26 (60.5)183 (44.7).12 Prosthetic201 (44.5)13 (30.3)188 (46.0) Hardware non–prosthetic joint42 (9.3)4 (9.3)38 (9.3)Source tissue Synovial fluid268 (59.3)21 (48.8)247 (60.4).12 Bone83 (18.4)13 (30.2)70 (17.1) Tissue77 (17.0)8 (18.6)69 (16.9) Body fluid19 (4.2)0 (0)19 (4.6) Bursa fluid5 (1.1)1 (2.3)4 (1.0)Pre-16S antibiotic exposurea Yes266 (58.9)33 (76.7)233 (57.0) <.01 No186 (41.1)10 (23.3)176 (43.0)Infectious Disease consult Yes292 (64.6)37 (86.1)255 (62.3) <.01 No160 (35.4)6 (14.0)154 (37.7)Diagnostic microbiologyb Micro+147 (32.5)22 (51.2)125 (30.6) <.01 Micro-305 (67.5)21 (48.8)284 (69.4)Judged diagnosisc Infectious252 (55.8)39 (90.7)213 (52.1) <.01 Noninfectious200 (44.2)4 (9.3)196 (47.9) aPre-16S antibiotic exposure is defined as antibiotic exposure before the 16S sample order. bDiagnostic microbiology includes gram stain and culture information from the same site as the 16S sample or other body sites that contribute to the diagnosis such as blood cultures. Positive microbiology (Micro+) is defined as bacteria detected on gram stain or bacterial growth on cultures. Negative microbiology (Micro-) is defined as no bacteria detected on gram stain and no bacterial growth on cultures. cEach episode was judged to be infectious or noninfectious by the treating clinical service's documentation and antibiotic plan. Qualitative Analysis of 16S Results (n = 452) aPre-16S antibiotic exposure is defined as antibiotic exposure before the 16S sample order. bDiagnostic microbiology includes gram stain and culture information from the same site as the 16S sample or other body sites that contribute to the diagnosis such as blood cultures. Positive microbiology (Micro+) is defined as bacteria detected on gram stain or bacterial growth on cultures. Negative microbiology (Micro-) is defined as no bacteria detected on gram stain and no bacterial growth on cultures. cEach episode was judged to be infectious or noninfectious by the treating clinical service's documentation and antibiotic plan. Table 2.Predictors of 16S PositivityOR95% CI P ValueDemographics Age, y0.990.98–1.00.26 Male gender1.240.65–2.35.51Indication Septic arthritisRefRefRef Osteomyelitis2.041.02–4.07 .04 Surgical site infection5.170.95–28.10.06 Bursitis3.230.35–30.08.30 Skin/soft tissue infection8.611.37–54.14 .02 Type of infection NativeRefRefRef Prosthetic0.490.24–0.98 .04 Hardware-associated non–prosthetic joint0.740.24–2.25.60Source tissue Synovial fluidRefRefRef Bone2.181.04–4.58 .04 Tissue1.360.58–3.21.48 Bursa fluid2.940.31–27.51.24Clinical characteristicsPre-16S antibiotic exposurea2.491.20–5.19 .02 Infectious Disease consult3.721.54–9.03 <.01 Positive diagnostic microbiology (Micro+)b2.381.26–4.49 <.01 Abbreviation: OR, odds ratio. aPre-16S antibiotic exposure is defined as antibiotic exposure before the 16S sample order. bDiagnostic microbiology includes gram stain and culture information from the same site as the 16S sample or other body sites that contribute to the diagnosis such as blood cultures. Positive microbiology (Micro+) is defined as bacteria detected on gram stain or bacterial growth on cultures. Predictors of 16S Positivity Abbreviation: OR, odds ratio. aPre-16S antibiotic exposure is defined as antibiotic exposure before the 16S sample order. bDiagnostic microbiology includes gram stain and culture information from the same site as the 16S sample or other body sites that contribute to the diagnosis such as blood cultures. Positive microbiology (Micro+) is defined as bacteria detected on gram stain or bacterial growth on cultures. The majority of episodes were judged infectious by the treating clinical services (55.8%, 252/452) (Table 3). While 16S+ results occurred in both the infectious (15.5%, 39/252) and noninfectious categories (2%, 4/200), 16S+ episodes were significantly more likely to be infectious than noninfectious (P ≤ .01). Overall, for diagnosing infectious episodes, 16S had a sensitivity of 15.5%, a specificity of 98%, a positive predictive value (PPV) of 90.7%, and a negative predictive value (NPV) of 47.9%. These results were heavily influenced by the diagnostic accuracy of the 16S tests from synovial fluid—the most common sampling site (sensitivity, 14.2%; specificity, 97%; PPV, 81.0%; NPV, 58.3%). The 16S performed best in the low numbers of bursa fluid (sensitivity, 25%; specificity, 100%) and bone (sensitivity, 21.6%; specificity, 100%). Table 3.Qualitative Results by Diagnosis (n = 452)aOverallInfectious (n = 252), No. (%)Noninfectious (n = 200), No. (%) P ValueAge Mean, y54.951.858.8 <.01 Gender Male252 (55.7)142 (56.3)110 (55.0).77 Female200 (44.3)110 (43.7)90 (45.0)Indication Septic arthritis320 (70.8)156 (61.9)164 (82.0) <.01 Osteomyelitis110 (24.3)78 (31.0)32 (16.0) Surgical site infection7 (1.6)6 (2.4)1 (0.5) Bursitis5 (1.1)4 (1.6)1 (0.5) Skin/soft tissue infection5 (1.1)4 (1.6)1 (0.5) Tenosynovitis5 (1.1)4 (1.6)1 (0.5)Type of infection Native209 (46.2)147 (58.3)62 (31.0) <.01 Prosthetic201 (44.5)82 (32.5)119 (59.5) Hardware nonprosthetic42 (9.3)23 (9.1)19 (9.5)Source tissue Synovial fluid268 (59.3)120 (47.6)148 (74.0) <.01 Bone83 (18.4)60 (23.8)23 (11.5) Tissue77 (17.0)53 (21.0)24 (12.0) Body fluid19 (4.2)15 (6.0)4 (2.0) Bursa fluid5 (1.1)4 (1.6)1 (0.5)Pre-16S antibiotic exposureb Yes266 (58.9)222 (88.1)44 (22.0) <.01 No186 (41.1)30 (11.9)156 (78.0)Infectious Disease consult Yes292 (64.6)235 (93.2)57 (28.5) <.01 No160 (35.4)17 (6.8)143 (71.5)Diagnostic microbiologyc Micro+147 (32.5)122 (48.4)25 (12.5) <.01 Micro-305 (67.5)130 (951.6)175 (87.5)16S result 16S+43 (9.5)39 (15.5)4 (2.0) <.01 16S-409 (90.5)213 (84.5)196 (98.0) aEach episode was judged to be infectious or noninfectious by the treating clinical service's documentation and antibiotic plan. bPre-16S antibiotic exposure is defined as antibiotic exposure before the 16S sample order. cDiagnostic microbiology includes gram stain and culture information from the same site as the 16S sample or other body sites that contribute to the diagnosis such as blood cultures. Positive microbiology (Micro+) is defined as bacteria detected on gram stain or bacterial growth on cultures. Negative microbiology (Micro-) is defined as no bacteria detected on gram stain and no bacterial growth on cultures. Qualitative Results by Diagnosis (n = 452)a aEach episode was judged to be infectious or noninfectious by the treating clinical service's documentation and antibiotic plan. bPre-16S antibiotic exposure is defined as antibiotic exposure before the 16S sample order. cDiagnostic microbiology includes gram stain and culture information from the same site as the 16S sample or other body sites that contribute to the diagnosis such as blood cultures. Positive microbiology (Micro+) is defined as bacteria detected on gram stain or bacterial growth on cultures. Negative microbiology (Micro-) is defined as no bacteria detected on gram stain and no bacterial growth on cultures. Organisms identified via 16S included S. aureus (11.6%, 5/43), Staphylococcus epidermidis (7.0%, 3/43), Viridans streptococci (7.0%, 3/43), Clostridium species (7.0%, 3/43), Corynebacterium tuberculostearicum (4.7%, 2/43), Staphylococcus lugdunensis (4.7%, 2/43), Staphylococcus species (4.7%, 2/43), Streptococcus dysgalactiae (4.7%, 2/43), Streptococcus intermedius (4.7%, 2/43), and Streptococcus pneumoniae (4.7%, 2/43). Anaerococcus species, Bacillus species, Enterobacter species, Fusobacterium species, Kingella kingae, Mycoplasma species, Neisseria gonorrhea, Paracoccus species, Pedobacter species, Planococcus species, P. aeruginosa, Serratia marcescens, Streptococcus agalactiae, Streptococcus bovis, Streptococcus pyogenes, and Streptococcus species were each identified once (2.3%, 1/43). Culture was able to identify the majority of the species identified by 16S; however, Anaerococcus species, Bacillus species, Pedobacter species, Fusobacterium species, K. kingae, and Mycoplasma species were identified through 16S amplification alone. Nearly half the infectious episodes had corresponding positive microbiology (48.4%, 122/252). In Subgroup H (infectious 16S+/Micro+) “16S redundant” episodes, the 16S and corresponding microbiology data matched appropriately, with (1) 16S amplifying the same organism that eventually grew late from the same anatomic site as 16S (50%, 11/22), (2) 16S matching an organism that grew from a different corresponding body site (45.5%, 10/22), or (3) 16S identifying an organism seen on gram stain that failed to grow on culture (4.5%, 1/22). All positive microbiology in noninfectious episodes (12.5%, 25/200) was judged to be contaminants by the treating clinical services. 16S Impact on Antibiotic Use Analysis of all episodes demonstrated antibiotic de-escalation from the pre-16S to post-16S time points (Table 4). The total number of antibiotics, number of parenteral antibiotics, and spectrum of antibiotic activity decreased, while the number of oral antibiotics increased. This de-escalation mirrors the strategy of initial broad empiric parenteral antibiotic therapy that is reduced in number, route, and spectrum of antibiotics with time and greater diagnostic clarity. Table 4.Analysis of Antibiotic PrescribingOverall Pre-16S and Post-16S Antibioticsa (Total Episodes, n = 452)Pre-16S AntibioticsPost-16S Antibiotics P ValueMean (SD)Mean (SD)IV antibiotics0.87 (0.91)0.54 (0.72) <.01 PO antibiotics0.15 (0.40)0.30 (0.56) <.01 Antipseudomonals0.21 (0.43)0.10 (0.33) <.01 Anti-MRSAs0.45 (0.53)0.24 (0.50) <.01 AntibioticsTimeMean Difference95% CI P Value1 P Value2Infectious 16S+/Micro- vs noninfectious 16S-/Micro- (Subgroups I vs O)Total antibioticsPre-16S1.41–1.9 <.01 …Post-16S2.21.7–2.7 <.01 <.01 IV antibioticsPre-16S1.51–2 <.01 …Post-16S2.92.1–3.8 <.01 <.01 PO antibioticsPre-16S0.9−0.6–2.9.24…Post-16S1.60.9–2.4 <.01 <.01 AntipseudomonalsPre-16S2.21.2–3.1 <.01 …Post-16S4.12–6.2 <.01 <.01 Anti-MRSAsPre-16S10.2–1.8.013…Post-16S1.50.6–2.4 <.01 <.01 Infectious 16S+/Micro+ vs infectious 16S+/Micro- (Subgroup H vs I)Total antibioticsPre-16S0.2−0.3–0.7.35…Post-16S−0.1−0.6–0.4.69.46IV antibioticsPre-16S0.1−0.4–0.6.70…Post-16S0.2−0.4–0.9.52.53PO antibioticsPre-16S1.1−0.4–2.7.15…Post-16S−1−2–0.1.08.04AntipseudomonalsPre-16S−0.5−1.6–0.5.31…Post-16S−1−2.3–0.4.18.54Anti-MRSAsPre-16S0.5−0.3–1.3.25…Post-16S0.2−0.8–1.1.69.98Infectious 16S+/Micro- vs infectious 16S-/Micro+ (Subgroup I vs J)Total antibioticsPre-16S0−0.4–0.4.95…Post-16S0−0.4–0.4.92.91IV antibioticsPre-16S0.1−0.3–0.5.65…Post-16S−0.1−0.7–0.4.68.35PO antibioticsPre-16S−0.7−2.1–0.8.36…Post-16S0.3−0.4–1.44.37AntipseudomonalsPre-16S0.4−0.4–1.2.33…Post-16S0.7−0.3–1.6.15.42Anti-MRSAsPre-16S−0.3−1–0.5.46…Post-16S−0.2−1–0.6.63.74Infectious 16S+/Micro- vs infectious 16S-/Micro- (Subgroup I vs K)Total antibioticsPre-16S−0.1−0.5–0.4.75…Post-16S0.1−0.3–0.5.68.73IV antibioticsPre-16S0−0.4–0.5.96…Post-16S0−0.5–0.6.89.84PO antibioticsPre-16S−0.7−2.2–0.7.31…Post-16S0.2−0.5–0.9.58.43AntipseudomonalsPre-16S0.4−0.4–1.1.35…Post-16S0.7−0.2–1.7.11.45Anti-MRSAsPre-16S−0.4−1.1–0.3.27…Post-16S−0.4−1.2–0.4.34.55Abbreviations: IV, intravenous; Mean, mean number of antibiotics; MRSA, methicillin-resistant Staphylococcus aureus. aPre-16S antibiotics are defined as antibiotic administration in the electronic medical record (EMR) at the time of the 16S order. Post-16S antibiotics are defined as antibiotic administration in the EMR after the reported 16S result. 1Comparisons between groups at pre-16S and post-16S. 2Comparisons between groups post-16S adjusted for the number of antibiotics administered at pre-16S. Analysis of Antibiotic Prescribing Abbreviations: IV, intravenous; Mean, mean number of antibiotics; MRSA, methicillin-resistant Staphylococcus aureus. aPre-16S antibiotics are defined as antibiotic administration in the electronic medical record (EMR) at the time of the 16S order. Post-16S antibiotics are defined as antibiotic administration in the EMR after the reported 16S result. 1Comparisons between groups at pre-16S and post-16S. 2Comparisons between groups post-16S adjusted for the number of antibiotics administered at pre-16S. The impact of 16S positivity on antibiotic prescribing was calculated by comparing antibiotic use between subgroups (Table 4). First, infectious 16S+/Micro- episodes were compared with noninfectious 16S-/Micro- episodes (Figure 1: Subgroup I [infectious 16S+/Micro-] “16S dependent” vs Subgroup O [noninfectious 16S-/Micro-] “infection ruled out”). As anticipated, episodes judged to be noninfectious received significantly lower numbers of post-16S antibiotics, parenteral antibiotics, oral antibiotics, antipseudomonal, and anti-MRSA antibiotics compared with those judged to be infectious via 16S+ (Table 4). The impact of 16S positivity on antibiotic prescribing for infectious episodes was calculated by comparing pre-16S and post-16S prescribing in (1) Subgroup H [infectious 16S+/Micro + ] “16S redundant” vs Subgroup I [infectious 16S+/Micro-] “16S dependent”, (2) Subgroup I [infectious 16S+/Micro-] “16S dependent” vs Subgroup J [infectious 6S-/Micro + ] “Culture diagnosed”, and (3) Subgroup I [infectious 16S+/Micro-] “16S dependent” versus Subgroup K [infectious 16S-/Micro-] “Diagnosed via history and physical” (Figure 1). When comparing these subgroups, we found no statistical difference in number of pre-16S or post-16S antibiotics, number of parenteral antibiotics, or spectrum of antibiotic activity (Table 4). CONCLUSIONS 16S rRNA bacterial identification aided in the diagnosis and treatment of only a minority of orthopedic infections. 16S’ ability to amplify a wide range of gram-positive, gram-negative, anaerobic, and atypical organisms was seen in our results [3]. As anticipated, the majority of identified pathogens were the gram-positive Staphylococcal or Streptococcal species that are commonly associated with orthopedic infections. Unlike traditional culture-based methods, we found that the yield of 16S is not negatively impacted by antibiotic pretreatment [4, 5]. Moreover, we found that antibiotic pretreatment was a predictor of 16S positivity (odds ratio, 2.49; 95% CI, 1.20–5.19), which likely reflects the clinical team’s high pretest suspicion of infection rather than any direct antibiotic effect on amplifying rRNA. The exceptional sensitivity of 16S is both a strength and a flaw. False positive 16S amplification can detect trace and nonviable bacterial rRNA contaminants acquired during collection and processing [6]. Rarely, noninfectious episodes had a false positive 16S result (2%, 4/200) (Figure 1: Subgroup N [noninfectious 16S-/Micro+] “false positive cultures”). The identified organisms were 3 undifferentiated Clostridium species and 1 Planococcus species. Planococcus and Clostridium species can both be true pathogens in orthopedic infections [7, 8]. These 4 episodes had negative corresponding microbiologic workup, and treating clinicians determined these 16S results to be inconsistent with the clinical history. In retrospective chart review, there was no evidence of untreated infection, recurrent infection, or poor outcomes in these false-positive episodes. The high number of infectious episodes in Subgroup J (infectious 16S-/Micro+; “culture diagnosed”; n = 100) is unexpected due to the reported high sensitivity of 16S. Episodes could have multiple cultures sent from multiple anatomic sites such as bone, tissue, synovial fluid, and blood but not a corresponding 16S for each specific anatomic site. In evaluation of Subgroup J (infectious 16S-/Micro+; “culture diagnosed”) samples, the positive microbiology was from a different anatomic site than that of the 16S in the majority of cases (69/100), which may have contributed to the unanticipated lower yield of 16S in these episodes with positive diagnostic microbiology. The high number infectious episodes in Subgroup K (infectious 16S-/Micro-; “diagnosed via history and physical”) defined as infectious episodes with both negative 16S and negative microbiology is surprising (Figure 1: Subgroup K, 44.8%, 113/252 episodes). These episodes were judged to be infectious based on history and physical exam alone without the aid of any molecular or culture-based microbiologic evidence. Moreover, these episodes illustrate that negative 16S results do not regularly dissuade treating clinical services from the possibility of infection. Possibilities to explain the high number of episodes in this subgroup include culture-negative infection, misdiagnosis, reliance on nonmicrobiologic diagnostics, and distrust of negative 16S results. Culture-negative orthopedic infections are reported to be as high as 42% in certain orthopedic device–related infections and may be secondary to low yield of the organisms associated with biofilms, prolonged incubation times, antibiotic pretreatment, and lack of enriched culture medium [9]. The risk of misdiagnosis as infection was likely mitigated by combined Orthopedic and Infectious Disease consultation in the majority of episodes (90.3%, 102/113). The high number of episodes judged to be infectious despite negative 16S and negative microbiology highlights that history and physical exam remain the bedrock of medical diagnosis even in the era of molecular amplification. Pathogen identification via 16S alone occurred in a small minority of infectious episodes and demonstrates the benefits of bacterial amplification (6.7%, 17/252) (Figure 1: Subgroup I [infectious 16S+/Micro-] “16S dependent”). For these patients, pathogens identified via 16S decreased the risk of a misdiagnosis and created an opportunity for targeted antimicrobials. Furthermore, these episodes demonstrate how 16S can identify fastidious and difficult-to-grow organisms such as Kingella kingae and Mycoplasma species that otherwise did not or could not grow on culture. While the opportunity for targeted antimicrobials was available to clinicians, no statistical difference in antibiotic prescribing measured by number, route of administration, or spectrum of coverage was seen between all infectious subgroups despite varying amounts of available 16S and microbiologic data (Table 4). This lack of difference was not anticipated and may reflect the multitude of factors that influence a prescribing clinician's selection including drug intolerances, allergies, drug–drug interactions, route of administration, frequency of dosing, cost, availability, and outpatient antibiotic coverage. The role of 16S bacterial identification as a tool for antimicrobial stewardship in orthopedic infections has been investigated before with similar underwhelming results. A 2017 study in Ireland showed a trend of antibiotic de-escalation in 16S+ samples, but this was not statistically significant [10]. A retrospective cohort of 90 patients with mixed infections split evenly between 16S+ and 16S- groups demonstrated a greater number and duration of antibiotics in the 16S+ arm but showed no statistical difference in the number of antibiotics de-escalated after the 16S result returned [11]. The interplay between molecular diagnostics and stewardship warrants continued investigation. Our study cannot adequately measure the downstream benefit of pathogen identification via 16S. The ability to provide targeted, long-term antimicrobial suppression is of particular benefit for orthopedic infections in which infected in situ hardware may require prolonged antimicrobial use. In addition, identifying a pathogen has benefits including epidemiologic information and may provide diagnostic clarity, improving both physician and patient satisfaction. There are downsides to uniformly obtaining 16S amplification for the evaluation of all orthopedic infections. 16S did not contribute to the diagnosis or management of the majority of orthopedic infections, occasionally and needlessly duplicated the results known by standard bacterial cultures, and lacked antimicrobial susceptibility data. In addition, similar to any diagnostic test, false positives occur that could lead to diagnostic or therapeutic uncertainty. At the time of publication, the 16S test costs ∼$635 to run at our institution and is performed only twice per week. Waiting for 16S results may delay final disposition or antibiotic plans, further escalating cost. Situations in which 16S amplification may play a role include cases with antibiotic pretreatment, those in which fastidious organisms are suspected, or those where standard culture techniques are unrevealing. Our study has multiple limitations. Study data reflect only 1 Midwest academic institution, are retrospective, and are not contemporary. Prescribing practices may have changed with greater familiarity with the test. Post-16S antibiotics may have included antibiotics for treatment of infections outside the orthopedic site in question, which could influence assessment of de-escalation. The authors only had access to microbiologic data and notes from their home institution and therefore may have missed key microbiologic and treatment information obtained from an outside hospital. Episodes were categorized based on the clinical team's treatment decisions, and judgment on what was and was not infectious cannot be corroborated. Therefore, misdiagnosis by the clinical teams would lead to incorrect categorization of the episode. In addition, this study evaluated 16S amplification, not next-generation sequencing (NGS). NGS represents new diagnostic technology that has similar performance to targeted 16S diagnostics for the diagnosis of prosthetic joint infections, but its role in stewardship efforts is not well described [12]. While notable, Subgroup I (infectious 16S+/Micro- or “16S dependent”) infections were not common. This group represents 6.7% of all infections and 3.8% of all 16S orders. Clinicians should consider 16S for the evaluation of orthopedic infections as a last-ditch effort, usually with little benefit, but capable of profound and memorable advantages when successful. Supplementary Material Notes Author contributions. J.M. – concept development and design, data acquisition, analysis, writing. M.M. – data acquisition. A.S. – data acquisition. E.M. – data acquisition. W.R. – data acquisition. J.E. – analysis. M.S.L. – concept development and design, analysis, and writing. D.A. – concept development and design, data acquisition, analysis, writing. Data availability. The data underlying this article are available in the article and in its online Supplementary Data. Patient consent. This study does not include factors necessitating patient consent. Financial support. The authors received no financial support for the research, authorship, or publication of the article. Contributor Information Joseph A McBride, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA; Department of Pediatrics, University of Wisconsin-Madison, Madison, Wisconsin, USA. Memee Moua, Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin, USA. Alana Sterkel, Department of Pathology and Laboratory Science, University of Wisconsin-Madison, Madison, Wisconsin, USA. Eduard Matkovic, Department of Pathology and Laboratory Science, University of Wisconsin-Madison, Madison, Wisconsin, USA. William Rehrauer, Department of Pathology and Laboratory Science, University of Wisconsin-Madison, Madison, Wisconsin, USA. Jens Eickhoff, Department of Pediatrics, University of Wisconsin-Madison, Madison, Wisconsin, USA. Marin L Schweizer, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA. David Andes, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA. Supplementary Data Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. References Associated Data Supplementary Materials